Primary Orbital Melanoma: Presentation, Treatment, and Long-term Outcomes for 13 Patients

被引:12
|
作者
Rose, Anna M. [1 ,2 ,3 ]
Luthert, Philip J. [2 ]
Jayasena, Channa N. [3 ]
Verity, David H. [1 ]
Rose, Geoffrey E. [1 ,2 ]
机构
[1] Moorfields Eye Hosp, Orbital Serv, London, England
[2] UCL, Inst Ophthalmol, London, England
[3] Imperial Coll London, Dept Med, London, England
来源
FRONTIERS IN ONCOLOGY | 2017年 / 7卷
关键词
primary orbital melanoma; orbital malignancy; ocular melanoma; melanoma; orbital surgery; MALIGNANT-MELANOMA; UVEAL MELANOMA; BLUE NEVUS; TUMORS; METASTASIS; MANAGEMENT; FEATURES; LECTURE;
D O I
10.3389/fonc.2017.00316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Periocular melanoma is a rare but often deadly malignancy that arises in the uvea (commonest origin), conjunctiva or orbit (rarest primary site). Melanoma accounts for 5-10% of metastatic/secondary orbital malignancies, but only a tiny proportion of primary orbital neoplasia. Primary orbital melanoma (POM) is exceedingly rare, with approximately 50 cases reported to date. Methods: All patients seen in the orbital unit at a tertiary referral hospital (1991-2016) with a biopsy-proven diagnosis of POM were identified from a diagnostic database and were studied. The case notes, imaging, surgical approach, and histology were reviewed. Results: Thirteen patients (five male; 38%) presented with isolated malignant melanoma of the orbit, for which no other primary site was identified at presentation or during an average follow-up of 44 months (median 22; range 0-13 years). The patients presented between the ages of 40 and 84 years (mean 55.5; median 48 years) and typically gave a short history of rapidly increasing proptosis and eyelid swelling. On the basis of history, a malignant lesion was suspected in most patients and all underwent incisional biopsy, with debulking of the mass in 10 (77%) patients, and skin-sparing exenteration in 3/13 (23%). Ten patients underwent orbital radiotherapy and the survival to date ranged from 9 months to 14 years (mean 55 months; median 23 months); two patients received solely palliative care for widespread disease and one patient refused orbital radiotherapy. Five of the 13 (38%) patients died from the disease. Discussion: POM is a very rare malignancy, but clinical analysis of this cohort gives insight into disease presentation and prognosis. The tumor typically presents with a rapidly progressive, well-defined mass that is, in some cases, amenable to macroscopically intact excision. Unusual for malignant melanoma, some of these patients can show an unusually long period of quiescent disease after surgical debulking and radiotherapy.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
    Handel, Eleanor E.
    Mckeown, Janet
    Wei, Joe
    Kankaria, Roma A.
    Burnette, Hannah
    Johnson, Douglas B.
    Lawless, Aleigha
    Czapla, Juliane
    Sullivan, Ryan J.
    Albrecht, Lea Jessica
    Zimmer, Lisa
    Mangana, Joanna
    Dummer, Reinhard
    Kessels, Jolien I.
    Neyns, Bart
    Allayous, Clara
    Lebbe, Celeste
    Boatwright, Christina
    Mehnert, Janice M.
    Ottaviano, Margaret
    Ascierto, Paolo A.
    Czarnecka, Anna M.
    Rutkowski, Piotr
    Lo, Serigne N.
    V. Long, Georgina
    Menzies, Alexander M.
    Carlino, Matteo S.
    EUROPEAN JOURNAL OF CANCER, 2025, 215
  • [32] Treatment and Outcomes of Melanoma in Acral Location in Korean Patients
    Roh, Mi Ryung
    Kim, Jihyun
    Chung, Kee Yang
    YONSEI MEDICAL JOURNAL, 2010, 51 (04) : 562 - 568
  • [33] Long-term Outcomes of Surgical Approaches to the Treatment of Floppy Eyelid Syndrome
    Ezra, Daniel G.
    Beaconsfield, Michele
    Sira, Mano
    Bunce, Catey
    Shah-Desai, Sabrina
    Verity, David H.
    Uddin, Jimmy
    Collin, Richard
    OPHTHALMOLOGY, 2010, 117 (04) : 839 - 846
  • [34] Long-Term Skeletal Outcomes of Primary Hyperparathyroidism Patients After Treatment with Parathyroidectomy: A Systematic Review and Meta-Analysis
    Zhang, Lu
    Liu, Xiaomei
    Li, Hongwei
    HORMONE AND METABOLIC RESEARCH, 2018, 50 (03) : 242 - +
  • [35] Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma
    Boutros, Celine
    Belkadi-Sadou, Djaouida
    Marchand, Antoine
    Roy, Severine
    Routier, Emilie
    Robert, Caroline
    CURRENT ONCOLOGY REPORTS, 2023, 25 (09) : 989 - 996
  • [36] Long-Term Outcomes after Surgical Treatment of Jugular Foramen Schwannoma
    Fukuda, Masafumi
    Oishi, Makoto
    Saito, Akihiko
    Fujii, Yukihiko
    SKULL BASE-AN INTERDISCIPLINARY APPROACH, 2009, 19 (06): : 401 - 408
  • [37] Effects of Long-term Serial Passaging on the Characteristics and Properties of Cell Lines Derived From Uveal Melanoma Primary Tumors
    Mouriaux, Frederic
    Zaniolo, Karine
    Bergeron, Marjorie-Allison
    Weidmann, Cindy
    De la Fouchardiere, Arnaud
    Fournier, Frederic
    Droit, Arnaud
    Morcos, Mohib W.
    Landreville, Solange
    Guerin, Sylvain L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (13) : 5288 - 5301
  • [38] Long-term outcomes of eye-conserving treatment with Ruthenium106 brachytherapy for choroidal melanoma
    Verschueren, Karijn M. S.
    Creutzberg, Carien L.
    Schalij-Delfos, Nicoline E.
    Ketelaars, Martijn
    Klijsen, Floor L. L.
    Haeseker, Barbara I.
    Ligtenberg, Sabine M. B.
    Keunen, Jan E. E.
    Marijnen, Corrie A. M.
    RADIOTHERAPY AND ONCOLOGY, 2010, 95 (03) : 332 - 338
  • [39] Long-term survival after surgical treatment followed by adjuvant systemic therapy for primary duodenal melanoma
    Rodrigo Cañada Trofo Surjan
    Sergio do Prado Silveira
    Elizabeth Santana dos Santos
    Luciana Rodrigues de Meirelles
    Clinical Journal of Gastroenterology, 2020, 13 : 532 - 537
  • [40] Primary Chest Wall Ewing Sarcoma: Treatment and Long-Term Results
    Salimbene, Ottavia
    Viggiano, Domenico
    Muratori, Francesco
    Lo Piccolo, Roberto
    Facchini, Flavio
    Tamburini, Angela
    Campanacci, Domenico Andrea
    Voltolini, Luca
    Gonfiotti, Alessandro
    LIFE-BASEL, 2024, 14 (06):